Keywords: emea, supports, abbott, synagis, use, pediatric, chd

EMEA supports Abbott's Synagis for use in pediatric CHD cases of RSV

Article | 04 August 2003

Print This

The European Medicines Evaluation Agency has granted a positive opinion for the use of Abbott Laboratories' Synagis (palivizumab) in young ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in